Atlas of Genetics and Cytogenetics in Oncology and Haematology


Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

X Y 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 NA

IL23A (interleukin 23, alpha subunit p19)

Written2010-05Norimitsu Inoue
Department of Molecular Genetics, Osaka Medical Center for Cancer, Cardiovascular Diseases, Osaka, Osaka 537-8511, Japan

(Note : for Links provided by Atlas : click)

Identity

Alias_namesG-CSF related factor
Alias_symbol (synonym)SGRF
IL23P19
IL-23
IL-23A
P19
Other aliasMGC79388
HGNC (Hugo) IL23A
LocusID (NCBI) 51561
Atlas_Id 44517
Location 12q13.3  [Link to chromosome band 12q13]
Location_base_pair Starts at 56338879 and ends at 56340410 bp from pter ( according to hg19-Feb_2009)  [Mapping IL23A.png]
Local_order Centromere-CNPY2-PAN2-IL23A-STAT2-APOF-Telomere.
Fusion genes
(updated 2017)
Data from Atlas, Mitelman, Cosmic Fusion, Fusion Cancer, TCGA fusion databases with official HUGO symbols (see references in chromosomal bands)

DNA/RNA

 
  IL23A gene. The IL23A gene spans a region of 1531 bp composed of 4 exons [untranslated region (UTR), light blue; coding region, dark blue] with 328 bp, 99 bp, 147 bp and 467 bp in length, and 3 introns (brown) with 219 bp, 166 bp and 105 bp in length.
Description 4 exons.
Transcription The transcript is 1041 bp, with a 166 bp 5' untranslated region (UTR), a 570 bp coding sequence, and a 305 bp 3' UTR.
Pseudogene No pseudogene.

Protein

Note The IL23A protein (IL-23p19 subunit) is covalently linked to a p40 subunit (IL12B, IL-12p40), which is shared with IL-12, to form IL-23 (Oppmann et al., 2000). The IL23A protein requires IL12B for secretion. The receptor for IL-23 is formed by the association of a specific IL-23 receptor (IL23R) and IL-12Rbeta1 (IL12RB1), which is shared with the receptor for IL-12 (Parham et al., 2002). The receptor for IL-23 is constitutively associated with Jak2 (Janus kinase 2) and predominantly activates Stat3, with less Stat4 activation than IL-12.
 
  IL23A protein. The IL23A protein is composed of a signal peptide (light green) and a mature peptide (dark green) with four alpha-helices (dark yellow).
Description The protein consists of 189 amino acids and is 20.7 kD, comprising a 19 amino acid signal peptide and a mature peptide (170 amino acids, 18.7 kD).
Expression IL-23 is secreted by dendritic cells (DCs) and phagocytic cells activated with pathogens and pathogen-associated molecular patterns that act through toll-like receptors (TLRs) (Hunter, 2005; Kastelein et al., 2007; Goriely et al., 2008). The TLR2 ligand peptidoglycan, a cell wall component of Gram-positive bacteria, preferentially promotes the expression of IL23A but not IL12A through activation of a cytosolic receptor, nucleotide-binding oligomerization domain 2 (NOD2), with TLR2. Activation of the C-type lectins-Syc-CARD9 signaling pathway by the beta-glucan curdlan also induces IL-23 production by DCs (LeibundGut-Landmann et al., 2007). Prostaglandin E2 (PGE2) and ATP act on their G-protein-coupled receptors, EP2 and EP4 (PGE2) and P2Y (ATP), to enhance IL-23 production via an increase in cAMP concentration (Sheibanie et al., 2004; Yao et al., 2009; Schnurr et al., 2005). Lactic acid also facilitates IL-23 production (Shime et al., 2008). Although these factors themselves do not induce IL-23 production, they can shift the balance between IL-12 and IL-23 secretion by activated DCs or macrophages toward IL-23. Polarized Th1 and Th2 cells highly express IL23A mRNA but not IL12B mRNA (Oppmann et al., 2000). The roles of IL23A mRNA expression in T cells are unknown.
Function IL-23 receptor is mainly expressed on activated/memory T cells and natural killer (NK) cells. Monocytes, macrophage and DCs also express IL-23 receptor at low levels (Parham et al., 2002). Although IL-23 does not directly stimulate the initial differentiation of naive T cells to Th17 cells, it is essential for the full differentiation of Th17 cells and promotes their expansion and maintenance to induce IL-17A production (Korn et al., 2009). NKT cells (Rachitskaya et al., 2008) and innate lymphoid cells such as lymphoid tissue induce (LTi)-like cells (Takatori et al., 2009; Buonocore et al., 2010) express IL-23 receptor and retinoic-acid-related orphan receptor (ROR) gammat and produce IL-17 in response to IL-23. IL-1beta and IL-23 also costimulate gammadelta T cells to induce IL-17 production without T cell receptor engagement (Sutton et al., 2009).
Homology IL23A has homology with four-helix bundle cytokine family members such as IL12A (IL-12p35), IL-6, and G-CSF. IL23A and IL12A have the highest homology, with approximately 40% of sequence identity among this family.

Implicated in

Note
  
Entity Various cancers
Note Promotion of tumor incidence and growth
The expression of IL-23A mRNA is significantly elevated in various human cancers, such as melanoma, colon, ovarian, head and neck, lung, breast, and stomach cancers, when compared with adjacent normal tissues (Langowski et al., 2006). IL-23 upregulation is also observed in sera from multiple myeloma patients (Prabhala et al., 2010). A deficiency of IL23A promotes increased infiltration of cytotoxic T cells into the transformed tissue and mediates resistance to chemically induced tumors. IL-23 facilitates the induction of inflammation and angiogenesis in the tumor microenvironment and inhibits CD8+ T cells infiltration, thereby promoting tumor incidence and growth (Langowski et al., 2006; Langowski et al., 2007; Martin-Orozco and Dong, 2009). It has been suggested that IL-23 also suppresses carcinogenesis and metastasis in mouse models, where it acts independently of IL-17A (Teng et al., 2010). Stat3 signaling shifts the balance between IL-23 and IL-12 toward IL-23 in the tumor microenvironment (Kortylewski et al., 2009). In tumor-associated regulatory T cells, IL-23-activated Stat3 induces the upregulation of Foxp3 and IL-10.

Anti-tumor effects
In several mouse tumor models, IL-23 overexpression in tumors (Overwijk et al., 2006) or intratumoral injection of IL-23-introduced DCs (Hu et al., 2006) has been shown to induce tumoral infiltration of CD8+ T cells and to inhibit tumor growth. Systemic administration of IL-23 also suppresses the growth of a pre-existing tumor in mice (Kaiga et al., 2007).

  
  
Entity Ovarian cancer
Note The occurrence of specific single nucleotide polymorphisms (SNPs) in the IL23R gene is increased in ovarian cancer patients compared with controls (dbSNPs: rs10889677) and in advanced ovarian cancer stage (dbSNPs: rs11465817) (Zhang et al., 2010).
  
  
Entity Inflammation and inflammatory diseases
Note IL23A and IL23R knockout mice are resistant to the development of experimental autoimmune encephalomyelitis and collagen-induced arthritis (Hunter, 2005; Kastelein et al., 2007; Abraham and Cho, 2009; Korn et al., 2009). IL-23A deficiency or treatment with anti-IL-23A blocking antibodies suppresses intestinal inflammation induced in IL-10-deficient mice. Ubiquitous overexpression of IL-23A in mice results in multi-organ inflammation. Therefore, IL-23 upregulation is thought to promote many inflammatory and autoimmune diseases. Many SNPs in the IL23R gene are reported to be significantly associated with Crohn's disease, ulcerative colitis, psoriasis, and ankylosing spondylitis. In particular, an uncommon allele at Arg381Gln (dbSNP: rs11209026) in the IL23R gene is associated with protection from Crohn's diseases, ulcerative colitis, and psoriasis.
  
  
Entity T-cell-independent colitis
Note IL-23 is involved in bacteria-driven innate immune colitis in Rag-/- mice. Recently, Buonocore et al. reported that IL-23 induces IL-17 and IFN-gamma expression by innate lymphoid cells expressing Thy-1, Stem cell antigen 1 (Sca-1), RORgammat and IL23R to mediate acute and chronic innate immune colitis (Buonocore et al., 2010).
  

Bibliography

IL-23 and autoimmunity: new insights into the pathogenesis of inflammatory bowel disease.
Abraham C, Cho JH.
Annu Rev Med. 2009;60:97-110. (REVIEW)
PMID 18976050
 
Innate lymphoid cells drive interleukin-23-dependent innate intestinal pathology.
Buonocore S, Ahern PP, Uhlig HH, Ivanov II, Littman DR, Maloy KJ, Powrie F.
Nature. 2010 Apr 29;464(7293):1371-5.
PMID 20393462
 
How microorganisms tip the balance between interleukin-12 family members.
Goriely S, Neurath MF, Goldman M.
Nat Rev Immunol. 2008 Jan;8(1):81-6. (REVIEW)
PMID 18084185
 
Induction of potent antitumor immunity by intratumoral injection of interleukin 23-transduced dendritic cells.
Hu J, Yuan X, Belladonna ML, Ong JM, Wachsmann-Hogiu S, Farkas DL, Black KL, Yu JS.
Cancer Res. 2006 Sep 1;66(17):8887-96.
PMID 16951206
 
New IL-12-family members: IL-23 and IL-27, cytokines with divergent functions.
Hunter CA.
Nat Rev Immunol. 2005 Jul;5(7):521-31. (REVIEW)
PMID 15999093
 
Systemic administration of IL-23 induces potent antitumor immunity primarily mediated through Th1-type response in association with the endogenously expressed IL-12.
Kaiga T, Sato M, Kaneda H, Iwakura Y, Takayama T, Tahara H.
J Immunol. 2007 Jun 15;178(12):7571-80.
PMID 17548592
 
Discovery and biology of IL-23 and IL-27: related but functionally distinct regulators of inflammation.
Kastelein RA, Hunter CA, Cua DJ.
Annu Rev Immunol. 2007;25:221-42. (REVIEW)
PMID 17291186
 
IL-17 and Th17 Cells.
Korn T, Bettelli E, Oukka M, Kuchroo VK.
Annu Rev Immunol. 2009;27:485-517. (REVIEW)
PMID 19132915
 
Regulation of the IL-23 and IL-12 balance by Stat3 signaling in the tumor microenvironment.
Kortylewski M, Xin H, Kujawski M, Lee H, Liu Y, Harris T, Drake C, Pardoll D, Yu H.
Cancer Cell. 2009 Feb 3;15(2):114-23.
PMID 19185846
 
Swords into plowshares: IL-23 repurposes tumor immune surveillance.
Langowski JL, Kastelein RA, Oft M.
Trends Immunol. 2007 May;28(5):207-12. Epub 2007 Mar 28.
PMID 17395538
 
Syk- and CARD9-dependent coupling of innate immunity to the induction of T helper cells that produce interleukin 17.
LeibundGut-Landmann S, Gross O, Robinson MJ, Osorio F, Slack EC, Tsoni SV, Schweighoffer E, Tybulewicz V, Brown GD, Ruland J, Reis e Sousa C.
Nat Immunol. 2007 Jun;8(6):630-8. Epub 2007 Apr 22.
PMID 17450144
 
The IL-17/IL-23 axis of inflammation in cancer: friend or foe?
Martin-Orozco N, Dong C.
Curr Opin Investig Drugs. 2009 Jun;10(6):543-9. (REVIEW)
PMID 19513943
 
Novel p19 protein engages IL-12p40 to form a cytokine, IL-23, with biological activities similar as well as distinct from IL-12.
Oppmann B, Lesley R, Blom B, Timans JC, Xu Y, Hunte B, Vega F, Yu N, Wang J, Singh K, Zonin F, Vaisberg E, Churakova T, Liu M, Gorman D, Wagner J, Zurawski S, Liu Y, Abrams JS, Moore KW, Rennick D, de Waal-Malefyt R, Hannum C, Bazan JF, Kastelein RA.
Immunity. 2000 Nov;13(5):715-25.
PMID 11114383
 
Immunological and antitumor effects of IL-23 as a cancer vaccine adjuvant.
Overwijk WW, de Visser KE, Tirion FH, de Jong LA, Pols TW, van der Velden YU, van den Boorn JG, Keller AM, Buurman WA, Theoret MR, Blom B, Restifo NP, Kruisbeek AM, Kastelein RA, Haanen JB.
J Immunol. 2006 May 1;176(9):5213-22.
PMID 16621986
 
A receptor for the heterodimeric cytokine IL-23 is composed of IL-12Rbeta1 and a novel cytokine receptor subunit, IL-23R.
Parham C, Chirica M, Timans J, Vaisberg E, Travis M, Cheung J, Pflanz S, Zhang R, Singh KP, Vega F, To W, Wagner J, O'Farrell AM, McClanahan T, Zurawski S, Hannum C, Gorman D, Rennick DM, Kastelein RA, de Waal Malefyt R, Moore KW.
J Immunol. 2002 Jun 1;168(11):5699-708.
PMID 12023369
 
Elevated IL-17 produced by TH17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma.
Prabhala RH, Pelluru D, Fulciniti M, Prabhala HK, Nanjappa P, Song W, Pai C, Amin S, Tai YT, Richardson PG, Ghobrial IM, Treon SP, Daley JF, Anderson KC, Kutok JL, Munshi NC.
Blood. 2010 Apr 15. [Epub ahead of print]
PMID 20395418
 
Cutting edge: NKT cells constitutively express IL-23 receptor and RORgammat and rapidly produce IL-17 upon receptor ligation in an IL-6-independent fashion.
Rachitskaya AV, Hansen AM, Horai R, Li Z, Villasmil R, Luger D, Nussenblatt RB, Caspi RR.
J Immunol. 2008 Apr 15;180(8):5167-71.
PMID 18390697
 
Extracellular nucleotide signaling by P2 receptors inhibits IL-12 and enhances IL-23 expression in human dendritic cells: a novel role for the cAMP pathway.
Schnurr M, Toy T, Shin A, Wagner M, Cebon J, Maraskovsky E.
Blood. 2005 Feb 15;105(4):1582-9. Epub 2004 Oct 14.
PMID 15486065
 
Prostaglandin E2 induces IL-23 production in bone marrow-derived dendritic cells.
Sheibanie AF, Tadmori I, Jing H, Vassiliou E, Ganea D.
FASEB J. 2004 Aug;18(11):1318-20. Epub 2004 Jun 4.
PMID 15180965
 
Tumor-secreted lactic acid promotes IL-23/IL-17 proinflammatory pathway.
Shime H, Yabu M, Akazawa T, Kodama K, Matsumoto M, Seya T, Inoue N.
J Immunol. 2008 Jun 1;180(11):7175-83.
PMID 18490716
 
Interleukin-1 and IL-23 induce innate IL-17 production from gammadelta T cells, amplifying Th17 responses and autoimmunity.
Sutton CE, Lalor SJ, Sweeney CM, Brereton CF, Lavelle EC, Mills KH.
Immunity. 2009 Aug 21;31(2):331-41. Epub 2009 Aug 13.
PMID 19682929
 
Lymphoid tissue inducer-like cells are an innate source of IL-17 and IL-22.
Takatori H, Kanno Y, Watford WT, Tato CM, Weiss G, Ivanov II, Littman DR, O'Shea JJ.
J Exp Med. 2009 Jan 16;206(1):35-41. Epub 2008 Dec 29.
PMID 19114665
 
IL-23 suppresses innate immune response independently of IL-17A during carcinogenesis and metastasis.
Teng MW, Andrews DM, McLaughlin N, von Scheidt B, Ngiow SF, Moller A, Hill GR, Iwakura Y, Oft M, Smyth MJ.
Proc Natl Acad Sci U S A. 2010 May 4;107(18):8328-33. Epub 2010 Apr 19.
PMID 20404142
 
Prostaglandin E2-EP4 signaling promotes immune inflammation through Th1 cell differentiation and Th17 cell expansion.
Yao C, Sakata D, Esaki Y, Li Y, Matsuoka T, Kuroiwa K, Sugimoto Y, Narumiya S.
Nat Med. 2009 Jun;15(6):633-40.
PMID 19465928
 
Association of interleukin-23 receptor gene polymorphisms with risk of ovarian cancer.
Zhang Z, Zhou B, Zhang J, Chen Y, Lai T, Yan L, Liang A, Li Y, Wang Y, Chen Y, Zhang L, Xi MR.
Cancer Genet Cytogenet. 2010 Jan 15;196(2):146-52.
PMID 20082850
 

Citation

This paper should be referenced as such :
Inoue, N
IL23A (interleukin 23, alpha subunit p19)
Atlas Genet Cytogenet Oncol Haematol. 2011;15(2):191-194.
Free journal version : [ pdf ]   [ DOI ]
On line version : http://AtlasGeneticsOncology.org/Genes/IL23AID44517ch12q13.html


External links

Nomenclature
HGNC (Hugo)IL23A   15488
Cards
AtlasIL23AID44517ch12q13
Entrez_Gene (NCBI)IL23A  51561  interleukin 23 subunit alpha
AliasesIL-23; IL-23A; IL23P19; P19; 
SGRF
GeneCards (Weizmann)IL23A
Ensembl hg19 (Hinxton)ENSG00000110944 [Gene_View]
Ensembl hg38 (Hinxton)ENSG00000110944 [Gene_View]  chr12:56338879-56340410 [Contig_View]  IL23A [Vega]
ICGC DataPortalENSG00000110944
TCGA cBioPortalIL23A
AceView (NCBI)IL23A
Genatlas (Paris)IL23A
WikiGenes51561
SOURCE (Princeton)IL23A
Genetics Home Reference (NIH)IL23A
Genomic and cartography
GoldenPath hg38 (UCSC)IL23A  -     chr12:56338879-56340410 +  12q13.3   [Description]    (hg38-Dec_2013)
GoldenPath hg19 (UCSC)IL23A  -     12q13.3   [Description]    (hg19-Feb_2009)
EnsemblIL23A - 12q13.3 [CytoView hg19]  IL23A - 12q13.3 [CytoView hg38]
Mapping of homologs : NCBIIL23A [Mapview hg19]  IL23A [Mapview hg38]
OMIM605580   
Gene and transcription
Genbank (Entrez)AB030000 AF301620 AJ506993 AY359083 BC066267
RefSeq transcript (Entrez)NM_016584
RefSeq genomic (Entrez)
Consensus coding sequences : CCDS (NCBI)IL23A
Cluster EST : UnigeneHs.382212 [ NCBI ]
CGAP (NCI)Hs.382212
Alternative Splicing GalleryENSG00000110944
Gene ExpressionIL23A [ NCBI-GEO ]   IL23A [ EBI - ARRAY_EXPRESS ]   IL23A [ SEEK ]   IL23A [ MEM ]
Gene Expression Viewer (FireBrowse)IL23A [ Firebrowse - Broad ]
SOURCE (Princeton)Expression in : [Datasets]   [Normal Tissue Atlas]  [carcinoma Classsification]  [NCI60]
GenevestigatorExpression in : [tissues]  [cell-lines]  [cancer]  [perturbations]  
BioGPS (Tissue expression)51561
GTEX Portal (Tissue expression)IL23A
Human Protein AtlasENSG00000110944-IL23A [pathology]   [cell]   [tissue]
Protein : pattern, domain, 3D structure
UniProt/SwissProtQ9NPF7   [function]  [subcellular_location]  [family_and_domains]  [pathology_and_biotech]  [ptm_processing]  [expression]  [interaction]
NextProtQ9NPF7  [Sequence]  [Exons]  [Medical]  [Publications]
With graphics : InterProQ9NPF7
Splice isoforms : SwissVarQ9NPF7
PhosPhoSitePlusQ9NPF7
Domains : Interpro (EBI)4_helix_cytokine-like_core    4_helix_cytokine_core    IL-23_alpha   
Domain families : Pfam (Sanger)IL23 (PF16649)   
Domain families : Pfam (NCBI)pfam16649   
Conserved Domain (NCBI)IL23A
DMDM Disease mutations51561
Blocks (Seattle)IL23A
PDB (SRS)3D85    3D87    3DUH    3QWR    4GRW    5MJ3    5MJ4   
PDB (PDBSum)3D85    3D87    3DUH    3QWR    4GRW    5MJ3    5MJ4   
PDB (IMB)3D85    3D87    3DUH    3QWR    4GRW    5MJ3    5MJ4   
PDB (RSDB)3D85    3D87    3DUH    3QWR    4GRW    5MJ3    5MJ4   
Structural Biology KnowledgeBase3D85    3D87    3DUH    3QWR    4GRW    5MJ3    5MJ4   
SCOP (Structural Classification of Proteins)3D85    3D87    3DUH    3QWR    4GRW    5MJ3    5MJ4   
CATH (Classification of proteins structures)3D85    3D87    3DUH    3QWR    4GRW    5MJ3    5MJ4   
SuperfamilyQ9NPF7
Human Protein Atlas [tissue]ENSG00000110944-IL23A [tissue]
Peptide AtlasQ9NPF7
HPRD12026
IPIIPI00300835   
Protein Interaction databases
DIP (DOE-UCLA)Q9NPF7
IntAct (EBI)Q9NPF7
FunCoupENSG00000110944
BioGRIDIL23A
STRING (EMBL)IL23A
ZODIACIL23A
Ontologies - Pathways
QuickGOQ9NPF7
Ontology : AmiGOpositive regulation of T cell mediated cytotoxicity  positive regulation of defense response to virus by host  positive regulation of defense bespofs% to virus by host  positive regulation of T-helper 1 type immune response  positive regulation of T-helper 1 type immune response  positive regulation of T-helper 1 type immune response  positive regulation of T-helper 1 type immune response  cytokine activity  protein binding  extracellular region  inflammatory response  negative regulation of interleukin-10 production  positive regulation of granulocyte macrophage colony-stimulating factor production  positive regulation of interferon-gamma production  positive regulation of interferon-gamma production  positive regulation of interleukin-10 production  positive regulation of interleukin-10 production  positive regulation of interleukin-12 production  positive regulation of interleukin-17 production  positive regulation of tumor necrosis factor production  positive regulation of natural killer cell activation  positive regulation of natural killer cell proliferation  positive regulation of tissue remodeling  T cell proliferation  positive regulation of T cell proliferation  positive regulation of activated T cell proliferation  positive regulation of NF-kappaB import into nucleus  positive regulation of memory T cell differentiation  innate immune response  interleukin-23 receptor binding  positive regulation of osteoclast differentiation  positive regulation of transcription from RNA polymerase II promoter  tissue remodeling  positive regulation of inflammatory response  defense response to Gram-negative bacterium  positive regulation of NK T cell activation  positive regulation of NK T cell activation  positive regulation of NK T cell proliferation  defense response to virus  interleukin-23 complex  positive regulation of neutrophil chemotaxis  positive regulation of T-helper 17 type immune response  positive regulation of T-helper 17 cell lineage commitment  positive regulation of T-helper 17 cell lineage commitment  
Ontology : EGO-EBIpositive regulation of T cell mediated cytotoxicity  positive regulation of defense response to virus by host  positive regulation of defense response to virus by host  positive regulation of T-helper 1 type immune response  positive regulation of T-helper 1 type immune response  positive regulation of T-helper 1 type immune response  positive regulation of T-helper 1 type immune response  cytokine activity  protein binding  extracellular region  inflammatory response  negative regulation of interleukin-10 production  positive regulation of granulocyte macrophage colony-stimulating factor production  positive regulation of interferon-gamma production  positive regulation of interferon-gamma production  positive regulation of interleukin-10 production  positive regulation of interleukin-10 production  positive regulation of interleukin-12 production  positive regulation of interleukin-17 production  positive regulation of tumor necrosis factor production  positive regulation of natural killer cell activation  positive regulation of natural killer cell proliferation  positive regulation of tissue remodeling  T cell proliferation  positive regulation of T cell proliferation  positive regulation of activated T cell proliferation  positive regulation of NF-kappaB import into nucleus  positive regulation of memory T cell differentiation  innate immune response  interleukin-23 receptor binding  positive regulation of osteoclast differentiation  positive regulation of transcription from RNA polymerase II promoter  tissue remodeling  positive regulation of inflammatory response  defense response to Gram-negative bacterium  positive regulation of NK T cell activation  positive regulation of NK T cell activation  positive regulation of NK T cell proliferation  defense response to virus  interleukin-23 complex  positive regulation of neutrophil chemotaxis  positive regulation of T-helper 17 type immune response  positive regulation of T-helper 17 cell lineage commitment  positive regulation of T-helper 17 cell lineage commitment  
Pathways : KEGGCytokine-cytokine receptor interaction    Jak-STAT signaling pathway    Pertussis    Tuberculosis    Inflammatory bowel disease (IBD)    Rheumatoid arthritis   
REACTOMEQ9NPF7 [protein]
REACTOME PathwaysR-HSA-6785807 [pathway]   
NDEx NetworkIL23A
Atlas of Cancer Signalling NetworkIL23A
Wikipedia pathwaysIL23A
Orthology - Evolution
OrthoDB51561
GeneTree (enSembl)ENSG00000110944
Phylogenetic Trees/Animal Genes : TreeFamIL23A
HOVERGENQ9NPF7
HOGENOMQ9NPF7
Homologs : HomoloGeneIL23A
Homology/Alignments : Family Browser (UCSC)IL23A
Gene fusions - Rearrangements
Tumor Fusion PortalIL23A
Polymorphisms : SNP and Copy number variants
NCBI Variation ViewerIL23A [hg38]
dbSNP Single Nucleotide Polymorphism (NCBI)IL23A
dbVarIL23A
ClinVarIL23A
1000_GenomesIL23A 
Exome Variant ServerIL23A
ExAC (Exome Aggregation Consortium)ENSG00000110944
GNOMAD BrowserENSG00000110944
Genetic variants : HAPMAP51561
Genomic Variants (DGV)IL23A [DGVbeta]
DECIPHERIL23A [patients]   [syndromes]   [variants]   [genes]  
CONAN: Copy Number AnalysisIL23A 
Mutations
ICGC Data PortalIL23A 
TCGA Data PortalIL23A 
Broad Tumor PortalIL23A
OASIS PortalIL23A [ Somatic mutations - Copy number]
Somatic Mutations in Cancer : COSMICIL23A  [overview]  [genome browser]  [tissue]  [distribution]  
Mutations and Diseases : HGMDIL23A
LOVD (Leiden Open Variation Database)Whole genome datasets
LOVD (Leiden Open Variation Database)LOVD 3.0 shared installation
BioMutasearch IL23A
DgiDB (Drug Gene Interaction Database)IL23A
DoCM (Curated mutations)IL23A (select the gene name)
CIViC (Clinical Interpretations of Variants in Cancer)IL23A (select a term)
intoGenIL23A
NCG5 (London)IL23A
Cancer3DIL23A(select the gene name)
Impact of mutations[PolyPhen2] [SIFT Human Coding SNP] [Buck Institute : MutDB] [Mutation Assessor] [Mutanalyser]
Diseases
OMIM605580   
Orphanet
DisGeNETIL23A
MedgenIL23A
Genetic Testing Registry IL23A
NextProtQ9NPF7 [Medical]
TSGene51561
GENETestsIL23A
Target ValidationIL23A
Huge Navigator IL23A [HugePedia]
snp3D : Map Gene to Disease51561
BioCentury BCIQIL23A
ClinGenIL23A
Clinical trials, drugs, therapy
Chemical/Protein Interactions : CTD51561
Chemical/Pharm GKB GenePA29824
Clinical trialIL23A
Miscellaneous
canSAR (ICR)IL23A (select the gene name)
Probes
Litterature
PubMed232 Pubmed reference(s) in Entrez
GeneRIFsGene References Into Functions (Entrez)
CoreMineIL23A
EVEXIL23A
GoPubMedIL23A
iHOPIL23A
REVIEW articlesautomatic search in PubMed
Last year publicationsautomatic search in PubMed

Search in all EBI   NCBI

© Atlas of Genetics and Cytogenetics in Oncology and Haematology
indexed on : Tue Nov 21 14:53:17 CET 2017

Home   Genes   Leukemias   Solid Tumors   Cancer-Prone   Deep Insight   Case Reports   Journals  Portal   Teaching   

For comments and suggestions or contributions, please contact us

jlhuret@AtlasGeneticsOncology.org.